Clinical utility of HIV-1 genotyping and expert advice: The Havana trial

AIDS

Volumn 16, Issue 2, 2002, Pages 209-218

  Tural, Cristina ^a   Ruiz, Lidia ^a   Holtzer, Christopher ^b   Schapiro, Jonathan ^c   Viciana, Pompeyo ^d   González, Juan ^e   Domingo, Pere ^f   Boucher, Charles ^g,h   Rey Joly, C ^a   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Visible Genetics   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL SANT PAU   (Spain)

^g Virology Networks   (Netherlands)

^h UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiretroviral therapy; Expert advice; Genotypic resistance; HIV 1; Resistance mutations; Viral load; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXPERT SYSTEM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MULTICENTER STUDY; NONHUMAN; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; SPAIN; SPECIALTIES, MEDICAL; TREATMENT OUTCOME;

EID: 0037169170     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00010     Document Type: Article

References (29)

1. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
2. HIV-1: Gambling on the evolution of drug resistance?
3. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype
4. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort study
5. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
6. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study
7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine
8. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
9. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
10. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
11. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus
12. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral
13. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
14. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up
15. Impact of treatment guided by phenotypic or genotypic resistance test on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
16. Antiretroviral drug resistance testing in adults with HIV-1 infection - Recommendations of an International AIDS Society-USA Panel
17. Strategies for long-term success in the treatment of HIV infection
18. Drug-resistant genotyping in HIV-1 therapy
19. Time to genotype for selection of antiretroviral regimens in previously treated patients?
20. HIV genotype and phenotype arresting resistance?
21. Clinical experience and choice of drug therapy for human immunodeficiency virus disease
22. The relationship of clinic experience with advanced HIV and survival of women with AIDS
23. Physicians experience with the acquired immunodeficiency syndrome as a factor in patients survival
24. Clinical significance of drug resistance in HIV-1 infection
25. Drug-resistant HIV-1: The virus strikes back
26. Resisting resistance: Maximizing the durability of antiretroviral therapy
27. The role of genotypic resistance testing in selecting therapy for HIV
28. Antiretroviral therapy in adults: Updated recommendation of the International AIDS Society - USA Panel
29. A propsective randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6-months results